Carlo Incerti
Director/Board Member presso DYNE THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Carlo Incerti is currently the Chairman at EryDel SpA, Azafaros BV, Inversago Pharma, Inc., VectorY BV, and Numab Therapeutics AG.
He is also an Independent Director at Dyne Therapeutics, Inc. and an Operating Partner at Forbion Capital Partners Management Holding BV.
Additionally, he is a Member of the International Rare Diseases Research Consortium.
Dr. Incerti's former positions include being the Chairman at AGC Biologics SpA and Gotham Therapeutics Corp.
He also served as the Chairman at AGC Biologics SpA from 2018 to 2020.
Furthermore, he held the position of Senior Vice President-Global Market Access at Genzyme Corp.
from 1992 to 2018 and was the Chief Medical Officer & Senior Vice President at Genzyme Therapeutics Ltd.Dr. Incerti obtained his doctorate degree from Università degli Studi di Modena e Reggio Emilia in 1984.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
DYNE THERAPEUTICS INC
-.--% | 24/05/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Carlo Incerti
Società | Posizione | Inizio |
---|---|---|
DYNE THERAPEUTICS, INC. | Director/Board Member | 02/03/2022 |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Chairman | - |
EryDel SpA
EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Chairman | 20/11/2020 |
Azafaros BV
Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Chairman | 01/01/2020 |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Chairman | 01/11/2020 |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 01/01/2019 |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Director/Board Member | 01/05/2021 |
International Rare Diseases Research Consortium | Corporate Officer/Principal | - |
Precedenti posizioni note di Carlo Incerti
Società | Posizione | Fine |
---|---|---|
MOLMED S.P.A. | Chairman | 01/07/2020 |
░░░░░░ ░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
░░░ ░░░░░░░░ ░░░░░░░░░░░ ░░░ ░░░░░░░░░░░░░ | ░░░░░░░░ | - |
Formazione di Carlo Incerti
Università degli Studi di Modena e Reggio Emilia | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
DYNE THERAPEUTICS, INC. | Health Technology |
Aziende private | 12 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
AGC Biologics SpA
AGC Biologics SpA Pharmaceuticals: MajorHealth Technology AGC Biologics SpA engages in the research, development, manufacturing, and clinical validation of cell and gene therapies for the treatment of cancer and rare diseases. Its approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. It also conducts cell and gene therapy projects in collaboration with third parties, offering resources and expertise covering preclinical to Phase III trial activities. The company was founded by Claudio Bordignon on July 11, 1996 and is headquartered in Milan, Italy. | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
EryDel SpA
EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Health Technology |
The European Association for Bioindustries | |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Commercial Services |
International Rare Diseases Research Consortium | |
Azafaros BV
Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Health Technology |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Health Technology |
Gotham Therapeutics Corp.
Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Gotham Therapeutics Corp. develops and manufactures pharmaceutical medicines. The firm develops new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The company was founded by Samie Jaffrey in 2017 and is headquartered in New York, NY. | Health Technology |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Carlo Incerti